acute myeloid leukemia

NEW YORK -- Bioenvision (Nasdaq: BIVN) today announced interim results from the ongoing clinical studies of clofarabine in pediatric and adult acute leukemia trials which confirm clofarabine's outstanding profile observed in previous studies.

NEW YORK -- Bioenvision (Nasdaq: BIVN) announced today that an update of clinical data from continuing trials of clofarabine in pediatric and adult acute leukemia will be presented at the 6th International Symposium and Expert Workshop on Leukemia and Lymphoma in Amsterdam on March 17th-19th.

While the Princeton area clinical trial is for breast cancer only, Taxotere(R) is currently being tested in the following cancer types around the country: breast, ovarian, adult acute leukemia, pediatric tumors, melanoma, non-Hodgkin's lymphoma, soft tissue sarcoma, and cancers of the stomach, prostate, pancreas, bladder, cervix and head and neck.

While the Reading area clinical trial is for breast cancer only, Taxotere(R) is currently being tested in the following cancer types around the country: breast, ovarian, adult acute leukemia, pediatric tumors, melanoma, non-Hodgkin's lymphoma, soft tissue sarcoma, and cancers of the stomach, prostate, pancreas, bladder, cervix and head and neck.

While the Philadelphia area clinical trial is for breast cancer only, Taxotere(R) is currently being tested in the following cancer types around the country: breast, ovarian, adult acute leukemia, pediatric tumors, melanoma, non-Hodgkin's lymphoma, soft tissue sarcoma, and cancers of the stomach, prostate, pancreas, bladder, cervix and head and neck.

While the Nashville area clinical trial is for breast cancer only, Taxotere(R) is currently being tested in the following cancer types around the country: breast, ovarian, adult acute leukemia, pediatric tumors, melanoma, non-Hodgkin's lymphoma, soft tissue sarcoma, and cancers of the stomach, prostate, pancreas, bladder, cervix and head and neck.